Key result
Patients with gynecologic cancer undergoing chemotherapy had a higher myocardial extracellular volume fraction compared to healthy controls, which increased with the number of chemotherapy cycles.
Why the study?
Patients with gynecologic cancers experience side effects of chemotherapy cardiotoxicity, prompting quantification of CMR markers of myocardial fibrosis in those with low cardiovascular risk.
Does chemotherapy increase CMR markers of myocardial fibrosis in patients with gynecologic cancer and low cardiovascular risk?
Cross-Sectional (n=98)
No
Does chemotherapy increase CMR markers of myocardial fibrosis in patients with gynecologic cancer and low cardiovascular risk?
Patients with gynecologic cancer and low cardiovascular risk undergoing chemotherapy exhibit diffuse extracellular volume expansion on CMR, which increases with the number of chemotherapy cycles.
Answers are grounded in this paper and cite their sources.
ECV expansion on CMR after chemotherapy in low-risk patients warrants monitoring; leaves open whether changes predict clinical cardiotoxicity.
Background Patients with gynecologic cancers experience side effects of chemotherapy cardiotoxicity. We aimed to quantify cardiac magnetic resonance (CMR) markers of myocardial fibrosis in patients with gynecologic cancer and low cardiovascular risk who undergo chemotherapy. Methods This study is part of a registered clinical research. CMR T1 mapping was performed in patients with gynecologic cancer and low cardiovascular risk undergoing chemotherapy. The results were compared with those of age-matched healthy control subjects. Results 68 patients (median age = 50 years) and 30 control subjects were included. The median number of chemotherapy cycles of patients was 9.0 (interquartile range [IQR] 3.3–17.0). Extracellular volume fraction (ECV) (27.2% ± 2.7% vs. 24.5% ± 1.7%, P < 0.001) and global longitudinal strain (−16.2% ± 2.8% vs. −17.4% ± 2.0%, P = 0.040) were higher in patients compared with controls. Patients with higher chemotherapy cycles (>6 cycles) (n=41) had significantly lower intracellular mass indexed (ICMi) compared with both patients with lower chemotherapy cycles (≤6 cycles) (n=27) (median 27.44 g/m 2 [IQR 24.03–31.15 g/m 2 ] vs. median 34.30 g/m 2 [IQR 29.93–39.79 g/m 2 ]; P = 0.002) and the control group (median 27.44 g/m 2 [IQR 24.03–31.15 g/m 2 ] vs. median 32.79 g/m 2 [IQR 27.74–35.76 g/m 2 ]; P = 0.002). Patients with two or more chemotherapy regimens had significantly lower ICMi compared with both patients with one chemotherapy regimen (27.45 ± 5.16 g/m 2 vs. 33.32 ± 6.42 g/m 2 ; P < 0.001) and the control group (27.45 ± 5.16 g/m 2 vs. 33.02 ± 5.52 g/m 2 ; P < 0.001). The number of chemotherapy cycles was associated with an increase in the ECV (Standard regression coefficient [β] = 0.383, P = 0.014) and a decrease in the ICMi (β = -0.349, P = 0.009). Conclusion Patients with gynecologic cancer and low cardiovascular risk who undergo chemotherapy have diffuse extracellular volume expansion, which is obvious with the increase of chemotherapy cycles. Myocyte loss may be part of the mechanism in patients with a higher chemotherapy load. Clinical trial registration http://www.chictr.org.cn , identifier ChiCTR-DDD-17013450.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2023) conducted a cross-sectional in Gynecologic cancer with low cardiovascular risk (n=98). Chemotherapy vs. Healthy control subjects was evaluated on Extracellular volume fraction (ECV) (p=<0.001). Patients with gynecologic cancer undergoing chemotherapy had a higher myocardial extracellular volume fraction compared to healthy controls, which increased with the number of chemotherapy cycles.
Synapse has enriched 10 related papers. Consider them for comparative context: